卡维地洛对老年慢性心肾综合征患者血浆IL-6、IL-10水平的影响

目的:观察卡维地洛对慢性心衰合并肾功能不全(CRS)患者血浆IL-6、IL-10水平的影响。方法:将2011~2012年我院收治的60例CRS患者采用数字表分组法随机分为对照组和治疗组两组,对照组仅给予常规心力衰竭治疗,治疗组在接受常规心力衰竭治疗的基础上加用卡维地洛直至目标剂量。治疗6个月后比较两组患者的心功能、肾功能和血浆IL-6、IL-10的水平。结果:治疗6个月后,治疗组LVEDD、LVESD较治疗前明显缩小(P0.05),且明显小于对照组(P0.05),而LVEF比治疗前明显升高(P0.05),也明显高于对照组(P0.05);治疗组的血浆BUN、Cr和IL-6水平均较治疗前显著降低(P0.05),且均明显低于对照组(P0.05),血浆IL-10有上升趋势,但差异无统计学意义(P0.05)。治疗前后,对照组以上指标比较差别均无统计学意义(均P0.05)。结论:卡维地洛辅助治疗可显著降低CRS患者血浆IL-6水平,对血浆IL-10的影响不明显。

Effects of Carvedilol On the SerumLevels of Interleukin-6 and Interleukin-10 In the Elderly Patients With Cardiorenal Syndrome

Objective： To observe the effect of carvidilol on the serum level of IL-6 and IL-10 in elderly patients with cardiorenal syndrome. Methods： 60 patients diagnosed as cardiorenal Syndrome （CRS） were enrolled in this study and divided into routine treatment group（30 patients） and carvedilol treatment group（30 patients）. After treatment with carvedilol in titrating doses and persisting doses for 6 months, left ventricular ejection fraction （LVEF）and the plasma concentrations of BUN, Cr and the serum level of IL-6, IL-10 were measured and compared. Results： After being treated for six months, the LVEDD, LVESD were reduced significantly（P〈0.05）,which were smaller than those in the control group （P〈0.05）, while the LVEF increased significantly （P〈0.05） and was higher than that in the control group （P〈0.05）. The serum BUN, Cr and IL-6 levels were reduced significantly （P〈0.05） and smaller than those in the control group （P〈0.05）, while the IL-10 increased slightly and there was no statical significance （P〉0.05）. All the indexs mentioned above in the control group, there were no statical significance both at prior-treatment and post-treatment（P〉0.05）. Conclusion： Carvidilol could relieve the systemic inflammatory reaction and increase the IL-6 level but have little effect on IL-10 in cardiorenal syndrome patients.